Tech Company Financing Transactions
Kernal Biologics Funding Round
On 7/7/2022, Kernal Biologics received $25 million in Series A investment from Hummingbird Ventures, Amgen Ventures and Civilization Ventures.
Transaction Overview
Company Name
Announced On
7/7/2022
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
Hummingbird Ventures (Lead Investor) (Firat Ileri)
Proceeds Purpose
The new capital will extend Kernal's mRNA 2.0 platform and support the filing of an IND for Kernal's immuno-oncology candidate KR-335.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
At Kernal Bio, we aim to harness the power of our mRNA technology to provide cancer patients with treatments that give them the best chance of beating their disease -- while eliminating as many common side effects as possible. Our unique inside-out approach attacks diseases like cancer at the cellular level.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yusuf Erkul
Co-Founder
Cafer Ozdemir
President
Burak Yilmaz
VP - Bus. Development
Maria Grunwald
Browse more venture capital transactions:
Prev: 7/7/2022: Intain venture capital transaction
Next: 7/7/2022: Deshe Analytics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs